The influence of N-acetyl-transferase 2 polymorphism on rheumatoid arthritis activity

Clinical and Experimental Rheumatology

Volumn 22, Issue 1, 2004, Pages 99-102

  Pawlik, Andrzej ^a   Ostanek, Lidia ^a   Brzosko, Iwona ^a   Brzosko, Marek ^a   Dabrowska Zamojcin, Ewa ^a   Gawronska Szklarz, Barbara ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Genotypes; NAT2; Rheumatoid arthritis

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; C REACTIVE PROTEIN; GLUCOCORTICOID; METHOTREXATE; XENOBIOTIC AGENT; NAT2 PROTEIN, HUMAN;

ACETYLATION; ACETYLATOR PHENOTYPE; ADULT; AGED; ARTHROPATHY; ARTICLE; DISEASE ACTIVITY; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MORNING STIFFNESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RHEUMATOID ARTHRITIS; RISK FACTOR; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; HOSPITALIZATION; JOINT; MIDDLE AGED; PATHOPHYSIOLOGY;

ACETYLATION; ADULT; AGED; ARTHRITIS, RHEUMATOID; ARYLAMINE N-ACETYLTRANSFERASE; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JOINTS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SEVERITY OF ILLNESS INDEX;

EID: 1242286467     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. WORDSWORTH BP, STEDEFORD J, ROSENBERG WM et al.: Limited heterogeneity of the HLA class II contribution to susceptibility to rheumatoid arthritis is suggested by positive assocoations with HLA-DR4, DR1 and DRw10. Br J Rheumatol 1991; 30: 178-80.
2. WEYAND CM, McCARTHY TG, GORONZY JJ: Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J Clin Invest 1995; 95: 2120-26.
3. STASTNY P: Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978; 298: 869-71.
4. MEYER JM, EVANS TI, SMALL RE et al.: HLA-DRB1 genotype influences risk for and severity of rheumatoid arthritis. J Rheumatol 1999; 26: 1024-34.
5. REVEILE JD: The genetic contribution to the pathogenesis of rheumatoid arthritis. Curr Opin Rheumatol 1998; 10: 187-200.
6. TURNER S, CHERRY N: Rheumatoid arthritis in workers exposed to silica in the pottery industry. Occup Environ Med 2000; 57: 443-7.
7. SYMMONS DPM, BANKHEAD CR, HARRISON BJ et al.: Blood transfusion, smokinig, and obesity as risk factors for the development of rheumatoid arthritis: Results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 1997; 40: 1955-61.
8. SHICHIKAWA K, INOUE K, HIROTA S et al.: Changes in the incidende and prevalence of rheumatoid arthritis in Kamitonda, Wakayama, Japan, 1965-1996. Ann Rheum Dis 1999; 58: 751-6.
9. MICHAEL VV, ALISA KE: Cell cycle implications in the pathogenesis of rheumatoid arthritis. Front Biosci 2000; 5: 594-601.
10. MULLER-LADNER U, KRIEGSMANN J GAY RE et al.: Oncogenes in rheumatoid arthritis. Rheum Dis Clin North Am 1995; 21: 675-90.
11. HEIN DW, DOLL MA, RUSTAN TD et al.: Metabolic activation and deactivation of arylamine carcinogens by recobinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993; 14: 1633-38.
12. HEIN DW, RUSTAN TD, DOLL MA et al.: Acetyltransferases and susceptability to chemicals. Toxicol Lett 1992; 64-65: 123-30.
13. GAWROÑSKA-SZKLARZ B, LUSZAWSKA-KUTRZEBA T, CZAJA-BULSA G et al.: Relationship between acetylation polimorphism and risk of atopic disease. Clin Pharmacol Ther 1999; 65: 562-9.
14. GAWROÑSKA-SZKLARZ B, PAWLIK A, CZAJA-BULSA G et al.: Geotype of N-acetyltransferase (NAT 2) polymorphism in children with immunoglobulin E-mediated food alergy. Clin Pharmacol Ther 2001; 69: 372-8.
15. ROCHA L, GARCIA C, DE MENDONCA A et al.: N-acetyltransferase 2 (NAT 2) genotype and susceptibility to sporadic Alzheimer's disease. Pharmacogenetics 1999; 9: 9-15.
16. PAWLIK A, OSTANEK L, BRZOSKO I et al.: Increased genotype frequency of N-acetyltransferase 2 slow acetylation in patients with rheumatoid arthritis. Clin Pharm Ther 2002; 72: 319-25.
17. SPIELBERG SP: N-acetyltransferases: Pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm 1996; 24: 509-19.
18. CASCORBI I, BROCKMOLLER J, MROZIKIEWICZ PM et al.: Arylamine N-acetyltransferase activity in man. Drug Metab Rev 1999; 31: 489-502.
19. FELSON DT, ANDERSON JJ, BOERS M et al.: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 29-740.
20. GUSTINCICH S, MANFIOLETTI G, DEL SAL G et al.: A fast method for high-quality genomic DNA extraction from whole blood. Biotechniques 1991; 11: 298-302.
21. SPURR NK, GOUGH AC, CHINEGWUNDOCH FI et al.: Polymorphisms in drug-metabolizing enzymes as modifiers of cancer risk. Clin Chem 1995; 41: 1864-9.
22. LOPEZ-MENDEZ A, DANIEL WW, READING JC et al.: Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two. Arthritis Rheum 1993; 36: 1364-9
23. HOLM BC, XU HW, JACOBSSON L et al.: Rats made congenic for Oia 3 on chromosome 10 become susceptible to squalene-induced arthritis. Hum Mol Genet 2001; 10: 565-72.
24. JOE B, REMMERS EF, DOBBINS DE et al.: Genetic dissection of collagen-induced arthritis in Chromosome 10 quantitative trait locus speed congenic rats: Evidence for more than one regulatory locus and sex influences. Immunogenetic 2000; 51: 930-44.
25. LORENTZEN JC, ERLANDSSON H, MUSSENER A: Specific and long lasting protection from collagen induced arthritis and oil induced arthritis in DA rats by administration of immunogens. Scand J Immunol 1995; 42: 82-9.
26. KLEINAU S, ERLANDSSON H, HOLMDAHL R et al.: Adjuvant oils induce arthritis in the DA rat 1. Characterization of the disease and evidence for an immunological involvement. J Autoimmun 1991; 4: 871-80.
27. LORENTZEN JG, GLASER A, JACOBSSON L et al.: Identification of rat susceptibility loci for adjuvant-oil-induced arthritis. Proc Natl Acad Sci USA 1998; 95: 6383-87.
28. LARRSON P, KLEINAU S, HOLMDAHL R et al.: Homologous type II colagen-induced arthritis in rats. Characterization of the disease and demonstration of clinically distinct forms of arthritis in two strains of rats after immunization with the same collagen preparation. Arthritis Rheum 1990; 33: 693-701.
29. SVENDSEN AJ, HOLM NV, KYVIK K et al.: Relative importance of genetic effects in rheumatoid arthritis: Historical cohort study of Danish nationwide twin population. BMJ 2002; 324: 264.
30. UHLIG T, HAGEN KB, KVIEN TK: Current tobacco smoking, formal education, and the risk of rheumatoid arthritis. J Rheumatol 1999; 26: 47-54.
31. RECKNER OLLSON A, SKOGH T, WINGREN G: Co-morbidity and lifestyle, reproductive factors, and environmental exposures associated with rheumatoid arthritis. Ann Rheum Dis 2001; 60: 934-9.
32. KLOCKARS M, KOSKELA RS, JARVINEN E: Silica exposure and rheumatoid arthritis: A follow up study of granite workers 1940-81. Br Med J 1987; 294: 997-1000.